Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of ET-743 [trabectedin] Therapy in Metastatic Osteosarcoma

Trial Profile

Phase II Study of ET-743 [trabectedin] Therapy in Metastatic Osteosarcoma

Phase of Trial: Phase II

Latest Information Update: 03 Feb 2010

At a glance

  • Drugs Trabectedin (Primary)
  • Indications Osteosarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Dec 2009 Inclusion and exclusion criteria amended from NCT.
    • 17 Dec 2009 Actual end date (Sep 2003) added as reported by ClinicalTrials.gov.
    • 17 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top